StemXVivo Serum-Free Tumorsphere Media
StemXVivo Serum-Free Tumorsphere Media Summary
Semi-solid media formulated and optimized for tumorsphere formation.
- Shown to support sphere formation of seven tumor cell lines
- Lot-to-lot consistency reduces experimental variability
- Specially formulated and optimized for tumorsphere formation
Why Perform the Tumorsphere Assay Using Specially Formulated Media?
Tumorsphere assays, also called sphere-formation assays, are in vitro assays that assess stem cell characteristics of tumor cells. There are a number of variables that contribute to variation in data obtained from tumorsphere assays including the purity of the starting cell population, the type and quantity of media and supplements, and the potential for tumorspheres to aggregate.
To minimize experimental variability due to the media and supplements, R&D Systems offers StemXVivo® Serum-Free Tumorsphere Media, which is formulated and optimized for tumorsphere formation.
StemXVivo® Serum-Free Tumorsphere Media:
- Shown to support sphere formation of seven tumor cell lines.
- Formulated and optimized for efficient tumorsphere formation.
- Lot-to-lot consistency reduces experimental variability.
- 100 mL of StemXVivo® Serum-Free Tumorsphere Media.
Stability and Storage
Upon receipt, StemXVivo® Serum-Free Tumorsphere Media should be stored at =-20 °C in a manual defrost freezer. The media can be thawed at 2 °C to 8 °C or at room temperature. Thawed media can be aliquoted and stored at =-20°C in a manual defrost freezer for up to 3 months or used within two weeks when stored in the dark at 2 °C to 8 °C. Avoid repeated freeze-thaw cycles. Do not use this product beyond the expiration date.
This product contains human transferrin. The transferrin was tested at the donor level using an FDA licensed method and found to be non-reactive for anti-HIV-1/2 and Hepatitis B surface antigen. As no testing can offer complete assurance of freedom from infectious agents, this product should be handled as if capable of transmitting infection.
- FOR LABORATORY RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
- The safety and efficacy of this product in diagnostic or other clinical uses has not been established.
- This reagent should not be used beyond the expiration date indicated on the label.
- Results may vary with cells cultured by different methods.
Tumorspheres Formed from the MCF-7 Human Breast Cancer Cell Line. MCF-7 human breast cancer cells were suspended in StemXVivo®Serum-Free Tumorsphere Media (Catalog # CCM012) containing 2 U/mL Heparin (Tocris Catalog # 2812) and 0.8 µg/mL Hydrocortisone (Tocris, Catalog # 4093). The cells were plated at 3 x 104cells per well in a 6-well ultralow adhesion culture plate and cultured at 37°C and 5% CO2for 3-10 days to induce tumorsphere formation. Tumorspheres were imaged using a CloneSelect™Imager from Molecular Devices (New Milton) Limited.
Refer to the product datasheet for complete product details.
Briefly, tumorsphere formation can be induced using the following procedure
- Cells are suspended in StemXVivo Serum-Free Tumorsphere Media containing Heparin and Hydrocortisone
- Cells are cultured on low adhesion plates at 37 °C and 5% CO2
- Tumorspheres should form in 3-10 days
Reagents supplied in the StemXVivo® Serum-Free Tumorsphere Media (Catalog # CCM012):
- 100 mL of StemXVivo® Serum-Free Tumorsphere Media
- 15 mL conical tube
- Ultralow adhesion cell culture plates
- 37 °C and 5% CO2 incubator
- Benchtop Centrifuge
Cryopreservation of Stem Cells
Add 2 U/mL Heparin and 0.5 µ;g/mL Hydrocortisone to pre-warmed StemXVivo® Serum-Free Tumorsphere Media.
Resuspend cells in the supplemented media.
Transfer the cell suspension to ultralow adhesion plates.
Incubate cultures in a 5% CO2 and 37 °C incubator.
Tumorspheres should form in 3-10 days.
Citations for StemXVivo Serum-Free Tumorsphere Media
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 10
Filter your results:
Cancer stem cell-derived extracellular vesicles preferentially target MHC-II-macrophages and PD1+ T cells in the tumor microenvironment
Authors: P Gonzalez-C, Z Guo, T Ziglari, NM Claudio, KH Nguyen, N Oshimori, J Seras-Fran, F Pucci
PLoS ONE, 2023-02-03;18(2):e0279400. 2023-02-03
Polyploid giant cancer cells, EZH2 and Myc upregulation in mammary epithelial cells infected with high-risk human cytomegalovirus
Authors: Z Nehme, S Pasquereau, S Haidar Ahm, R El Baba, G Herbein
EBioMedicine, 2022-05-18;80(0):104056. 2022-05-18
Colon adenocarcinoma-derived cells possessing stem cell function can be modulated using renin-angiotensin system inhibitors
Authors: MJ Munro, L Peng, SK Wickremese, ST Tan
PLoS ONE, 2021-08-24;16(8):e0256280. 2021-08-24
Colon adenocarcinoma-derived cells that express induced-pluripotent stem cell markers possess stem cell function
Authors: MJ Munro, L Peng, SK Wickremese, ST Tan
PLoS ONE, 2020-05-19;15(5):e0232934. 2020-05-19
Identification of Cancer Stem Cell Subpopulations in Head and Neck Metastatic Malignant Melanoma
Authors: V Yoganandar, J Patel, B van Schaij, N Bockett, HD Brasch, E Paterson, D Sim, PF Davis, IM Roth, T Itinteang, ST Tan
Cells, 2020-01-30;9(2):. 2020-01-30
Metastatic renal cell carcinoma cells growing in 3D on poly?D?lysine or laminin present a stem?like phenotype and drug resistance
Authors: KK Brodaczews, ZF Bielecka, K Maliszewsk, C Szczylik, C Porta, E Bartnik, AM Czarnecka
Oncol. Rep., 2019-09-18;42(5):1878-1892. 2019-09-18
RER1 enhances carcinogenesis and stemness of pancreatic cancer under hypoxic environment
Authors: S Chen, J Zhang, J Chen, Y Wang, S Zhou, L Huang, Y Bai, C Peng, B Shen, H Chen, Y Tian
J. Exp. Clin. Cancer Res., 2019-01-10;38(1):15. 2019-01-10
TRPM7 overexpression enhances the cancer stem cell-like and metastatic phenotypes of lung cancer through modulation of the Hsp90?/uPA/MMP2 signaling pathway
Authors: K Liu, SH Xu, Z Chen, QX Zeng, ZJ Li, ZM Chen
BMC Cancer, 2018-11-26;18(1):1167. 2018-11-26
Role of SIRT2 in Regulation of Stemness of Cancer Stem-Like Cells in Renal Cell Carcinoma
Authors: R Wei, D He, X Zhang
Cell. Physiol. Biochem., 2018-09-27;49(6):2348-2357. 2018-09-27
The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear ?-catenin/c-Myc axis in OSCC
Authors: LH Wang, M Xu, LQ Fu, XY Chen, F Yang
Sci Rep, 2018-08-24;8(1):12776. 2018-08-24
Oncostatin M induces tumorigenic properties in non-transformed human prostate epithelial cells, in part through activation of signal transducer and activator of transcription 3 (STAT3)
Authors: S Sterbova, T Karlsson, E Persson
Biochem. Biophys. Res. Commun., 2018-03-12;0(0):. 2018-03-12
Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine
Authors: MH Cai, XG Xu, SL Yan, Z Sun, Y Ying, BK Wang, YX Tu
Sci Rep, 2018-01-26;8(1):1621. 2018-01-26
HCMV activates the IL-6-JAK-STAT3 axis in HepG2 cells and primary human hepatocytes.
Authors: Lepiller Q, Abbas W, Kumar A, Tripathy M, Herbein G
PLoS ONE, 2013-03-26;8(3):e59591. 2013-03-26
Can a 96-well ultra-low adhesion plate be used for Tumorsphere formation using Catalog # CCM012 (StemXVivo Serum-free Tumorsphere Media)? How many cells should be plated /well?
Yes. A 96-well ultra-low adhesion plate can be used for Tumorsphere formation. A recommended cell number is approximately 100 cells/well, but it is advisable to titrate and evaluate the optimal cell number.
Reviews for StemXVivo Serum-Free Tumorsphere Media
There are currently no reviews for this product. Be the first to review StemXVivo Serum-Free Tumorsphere Media and earn rewards!
Have you used StemXVivo Serum-Free Tumorsphere Media?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image